Novo Nordisk
NVO
NVO
553 hedge funds and large institutions have $8.16B invested in Novo Nordisk in 2018 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 156 increasing their positions, 206 reducing their positions, and 53 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
8% less capital invested
Capital invested by funds: $8.82B → $8.16B (-$665M)
24% less repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 206
26% less funds holding in top 10
Funds holding in top 10: 19 → 14 (-5)
Holders
553
Holding in Top 10
14
Calls
$51.7M
Puts
$16.3M
Top Buyers
1 | +$74.3M | |
2 | +$67M | |
3 | +$65.2M | |
4 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$32.4M |
5 |
Fisher Asset Management
Camas,
Washington
|
+$20.9M |
Top Sellers
1 | -$58M | |
2 | -$53.4M | |
3 | -$19.1M | |
4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$16.5M |
5 |
RBCM
Raub Brock Capital Management
Larkspur,
California
|
-$16.4M |